HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

Thursday, 23 July 2015

Elosulfase alfa (Vimizim) £395,000 per person per year…

…and it’s a minded no.  As part of the Highly Specialised Technologies programme, the “Committee requests that the company provides a further explanation of the cost of elosulfase alfa, in the context of development and manufacturing costs, the benefits it provides to people with the condition, and the budget impact on the NHS and Personal Social Services.”

What about NHS patient impact? With no published ICERs and the company’s estimate of life years gained of around 34 being cut to less than 3 in some of the ERG’s analyses, the impact on NHS patients is probably going to be quite high.